Lixisenatide
Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
| Trivial name | Lyxumia, Adlyxin, ZP10A peptide, AVE0010 |
| Catalog Number | S8517 |
| Molecular Formula | C215H347N61O65S |
| CAS# | 320367-13-3 |
| Inchi | InChI=1S/C215H347N61O65S/c1-16-115(10)173(210(337)254-141(67-73-169(297)298)194(321)259-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)256-143(89-111(2)3)196(323)248-136(58-32-40-83-223)191(318 )260-149(96-160(226)285)182(309)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)265-154(108-280)206(333)263-151(105-277)183(310)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214 (341)275-86-43-61-157(275)208(335)266-153(107-279)204(331)250-134(56-30-38-81-221)189(316)247-133(55-29-37-80-220)188(315)246-132(54-28-36-79-219)187(314)245-131(53-27-35-78-218)186(313)244-130(52-26- 34-77-217)185(312)243-129(178(227)305)51-25-33-76-216)270-201(328)146(92-120-45-19-17-20-46-120)258-197(324)144(90-112(4)5)255-192(319)137(59-41-84-231-215(228)229)253-209(336)172(114(8)9)269-179(306) 116(11)240-184(311)140(66-72-168(295)296)252-195(322)142(68-74-170(299)300)273-272-128(64-70-166(291)292)177(304)176(303)127(75-88-342-15)242-193(320)139(63-69-159(225)284)251-190(317)135(57-31-39-82- 222)249-203(330)152(106-278)264-198(325)145(91-113(6)7)257-200(327)150(97-171(301)302)261-205(332)155(109-281)267-212(339)175(119(14)283)271-202(329)147(93-121-47-21-18-22-48-121)262-211(338)174(118(1 3)282)268-164(289)103-236-181(308)138(65-71-167(293)294)241-163(288)102-234-180(307)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,272-273,277-283H,16,25-44,51-97 ,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,305)(H,230,238)(H,233,286)(H,234,307)(H,235,309)(H,236,308)(H,237,310)(H,239,287)(H,240,311)(H,241,288)(H,242,320)(H,243,312)(H,244,313)(H,245 ,314)(H,246,315)(H,247,316)(H,248,323)(H,249,330)(H,250,331)(H,251,317)(H,252,322)(H,253,336)(H,254,337)(H,255,319)(H,256,326)(H,257,327)(H,258,324)(H,259,321)(H,260,318)(H,261,332)(H,262,338)(H,263,3 33)(H,264,325)(H,265,334)(H,266,335)(H,267,339)(H,268,289)(H,269,306)(H,270,328)(H,271,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+, 125+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,172+,173+,174+,175+/m1/s1 |
| Inchi Key | YSIXJDSIUMNSGK-DPDNAOFASA-N |
| SMILES | CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N |
| Size | 5mg |
| Supplier Page | http://www.selleckchem.com/products/lixisenatide.html |
| Additional Information | https://file.selleck.cn/downloads/struct/lixisenatide-chemical-structure-S8517.gif |